secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2022-08-12T23:59:59+00:00
Accession:  0001654954-22-011202
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech Q3 net loss $5.79M ($0.37/sh); Phase 3 ARDS study expanded; Phase 2b on track
--------------------------------------------------------------------------------

- Net loss for Q3 fiscal 2022: $5.79M ($0.37/sh) vs $4.76M ($0.36/sh) in prior year; nine-month loss $14.74M ($1.04/sh).
- Phase 3 ARDS study for Covid-19 expanded to second cohort; parallel recruitment underway.
- Phase 2b ACD study expects to randomize all 210 subjects by Q4 2022 with topline data in early 2023.
- Cash and equivalents $12.81M; working capital $9.52M at June 30, 2022.
- Operating expenses for Q3 were $5.80M, down from $6.07M YoY, driven by lower G&A and share-based compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000165495422011202/0001654954-22-011202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000165495422011202/edsa_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-011202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer